Astellas reorganizes research framework, including closing OSI Pharma and Perseid
Japanese drug major Astellas Pharma (TYO: 4503) has announced plans to reshape its research framework by introducing new initiatives to further enhance the ability to generate innovative drugs.
The extraordinary losses of around11 billion yen ($108 million) have been accounted in the forecasts for the fiscal year ending March 2014 to reflect these initiatives. Details of specific initiatives are as follows:
Establish Astellas Innovation Management:
In order to enhance the process of screening external opportunities to strengthen innovation during the preclinical development stage, activities that are currently undertaken by multiple departments, including Astellas Venture Management (AVM), will be integrated with the establishment of Astellas Innovation Management (AIM), scheduled for October 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze